Interaction Checker

Glucagon interactions

Glucagon (GlucaGen, Gvoke, Baqsimi) has 87 documented interactions across the FDA labels and fact sheets we index: 35 major, 32 moderate, 20 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Major interactions (35)

  • AclidiniumanticholinergicMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • AmantadineanticholinergicMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • Amitriptylinetricyclic antidepressantMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • BenztropineanticholinergicMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • ChlorpheniramineantihistamineMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • ChlorpromazineantipsychoticMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • ClozapineantipsychoticMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • Cyclobenzaprinemuscle relaxantMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • CyclopentolateanticholinergicMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • DarifenacinanticholinergicMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • DicyclomineanticholinergicMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • DimenhydrinateantihistamineMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • DiphenhydramineantihistamineMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • Doxepintricyclic antidepressantMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • DoxylamineantihistamineMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • ExenatideGLP-1 receptor agonistMajor

    Acute Pancreatitis Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with glucagon-like peptide-1 (GLP-1) receptor agonists, including BYETTA [see Adverse Reactions (6.2) ] . (Exenatide label, Warnings and precautions)

  • FesoterodineanticholinergicMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • GlycopyrrolateanticholinergicMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • HydroxyzineantihistamineMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • HyoscyamineanticholinergicMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • IpratropiumanticholinergicMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • MeclizineantihistamineMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • Nortriptylinetricyclic antidepressantMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • OlanzapineantipsychoticMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • OxybutyninanticholinergicMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • ParoxetineSSRIMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • ProchlorperazineantipsychoticMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • PromethazineantihistamineMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • ScopolamineanticholinergicMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • SolifenacinanticholinergicMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • TiotropiumanticholinergicMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • TolterodineanticholinergicMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • TrihexyphenidylanticholinergicMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • TrospiumanticholinergicMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

  • Umeclidinium and vilanterolanticholinergicMajor

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glucagon label, Drug interactions)

Moderate interactions (32)

  • ApixabananticoagulantModerate

    Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Glucagon label, Drug interactions)

  • Atenololbeta blockerModerate

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glucagon label, Drug interactions)

  • Bisoprololbeta blockerModerate

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glucagon label, Drug interactions)

  • Bisoprolol and hydrochlorothiazidebeta blockerModerate

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glucagon label, Drug interactions)

  • Carvedilolbeta blockerModerate

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glucagon label, Drug interactions)

  • DabigatrananticoagulantModerate

    Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Glucagon label, Drug interactions)

  • Dorzolamide and timololcarbonic anhydrase inhibitorModerate

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glucagon label, Drug interactions)

  • EdoxabananticoagulantModerate

    Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Glucagon label, Drug interactions)

  • EnoxaparinanticoagulantModerate

    Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Glucagon label, Drug interactions)

  • Esmololbeta blockerModerate

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glucagon label, Drug interactions)

  • FondaparinuxanticoagulantModerate

    Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Glucagon label, Drug interactions)

  • GlimepiridesulfonylureaModerate

    The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics,… (Glimepiride label, Drug interactions)

  • GlipizidesulfonylureaModerate

    …glucose-lowering effect of GLUCOTROL XL, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (Glipizide label, Drug interactions)

  • HeparinanticoagulantModerate

    Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Glucagon label, Drug interactions)

  • IndomethacinNSAIDModerate

    Indomethacin Clincial Impact: In patients taking indomethacin, GVOKE may lose its ability to raise blood glucose or may even produce hypoglycemia. (Glucagon label, Drug interactions)

  • Insulin aspartinsulinModerate

    Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (Glucagon label, Warnings and precautions)

  • Insulin degludecinsulinModerate

    Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (Glucagon label, Warnings and precautions)

  • Insulin detemirinsulinModerate

    Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (Glucagon label, Warnings and precautions)

  • Insulin glargineinsulinModerate

    Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (Glucagon label, Warnings and precautions)

  • Insulin lisproinsulinModerate

    Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (Glucagon label, Warnings and precautions)

  • Insulin regular (human)insulinModerate

    Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (Glucagon label, Warnings and precautions)

  • Labetalolbeta blockerModerate

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glucagon label, Drug interactions)

  • Metoprololbeta blockerModerate

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glucagon label, Drug interactions)

  • Nadololbeta blockerModerate

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glucagon label, Drug interactions)

  • Nebivololbeta blockerModerate

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glucagon label, Drug interactions)

  • Pindololbeta blockerModerate

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glucagon label, Drug interactions)

  • Propranololbeta blockerModerate

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glucagon label, Drug interactions)

  • RivaroxabananticoagulantModerate

    Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Glucagon label, Drug interactions)

  • Sotalolbeta blockerModerate

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glucagon label, Drug interactions)

  • Timololbeta blockerModerate

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glucagon label, Drug interactions)

  • TirzepatideGLP-1 receptor agonistModerate

    Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (Glucagon label, Warnings and precautions)

  • WarfarinanticoagulantModerate

    Intervention Monitor patients for unusual bruising or bleeding, as adjustments in warfarin dosage may be required. (Glucagon label, Drug interactions)

Minor mentions (20)

  • BeclomethasonecorticosteroidMinor

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glucagon label, Warnings and precautions)

  • BetamethasonecorticosteroidMinor

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glucagon label, Warnings and precautions)

  • BudesonidecorticosteroidMinor

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glucagon label, Warnings and precautions)

  • Budesonide and formoterolcorticosteroidMinor

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glucagon label, Warnings and precautions)

  • ClobetasolcorticosteroidMinor

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glucagon label, Warnings and precautions)

  • DesonidecorticosteroidMinor

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glucagon label, Warnings and precautions)

  • DexamethasonecorticosteroidMinor

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glucagon label, Warnings and precautions)

  • DulaglutideGLP-1 receptor agonistMinor

    Glucagon-like peptide-1 (GLP-1) receptor agonists have induced thyroid C-cell adenomas and carcinomas in mice and rats at clinically relevant exposures. (Dulaglutide label, Warnings and precautions)

  • FludrocortisonecorticosteroidMinor

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glucagon label, Warnings and precautions)

  • FluocinonidecorticosteroidMinor

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glucagon label, Warnings and precautions)

  • FluticasonecorticosteroidMinor

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glucagon label, Warnings and precautions)

  • Fluticasone and salmeterolcorticosteroidMinor

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glucagon label, Warnings and precautions)

  • HalobetasolcorticosteroidMinor

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glucagon label, Warnings and precautions)

  • HydrocortisonecorticosteroidMinor

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glucagon label, Warnings and precautions)

  • MethylprednisolonecorticosteroidMinor

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glucagon label, Warnings and precautions)

  • MometasonecorticosteroidMinor

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glucagon label, Warnings and precautions)

  • PrednisolonecorticosteroidMinor

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glucagon label, Warnings and precautions)

  • PrednisonecorticosteroidMinor

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glucagon label, Warnings and precautions)

  • RepaglinidemeglitinideMinor

    Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and… (Repaglinide label, Drug interactions)

  • TriamcinolonecorticosteroidMinor

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glucagon label, Warnings and precautions)

Check Glucagon against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.